Advertisement

Issues in Oncology

UK-Based Survey Finds Cancer Is the Leading Health Concern Among the Public

A new survey conducted in the United Kingdom found two-thirds of the public say they are very or somewhat worried about being told they have cancer—a higher percentage than for any other medical condition, including dementia and having a heart attack—according to polling released today.

The...

Lymphoma

Advanced Classical Hodgkin Lymphoma: PET-Guided BrECADD vs eBEACOPP

As reported in The Lancet by Peter Borchmann, MD, and colleagues, the phase III HD21 trial showed that first-line positron-emission tomography (PET)-guided BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) exhibited greater efficacy and...

Skin Cancer
Issues in Oncology
Immunotherapy

High-Risk Melanoma: Inhibiting MEK and PD-L1 in Tandem

Cobimetinib and atezolizumab administered prior to surgery eliminated or shrunk tumors in 70% of patients with melanoma enrolled in the NeoACTIVATE trial. Results were published by Hieken et al in Nature Communications.

Background

Melanoma of the skin is the fifth most common cancer type in the...

Solid Tumors
Colorectal Cancer
Immunotherapy

Novel Immunotherapy Approach in Metastatic Solid Tumors

A novel personalized cellular immunotherapy approach may be effective at treating certain patients with metastatic solid tumors, according to early findings from a recent study published by Parkhurst et al in Nature Medicine.

Background

Chimeric antigen receptor (CAR) T-cell therapy has already...

Prostate Cancer

Prostate Cancer Detection With AI vs Radiologist Readings of MRI

In a study reported in The Lancet Oncology (PI-CAI), Saha et al found that an artificial intelligence (AI) system’s readings of magnetic resonance imaging (MRI) outperformed study radiologist readings using Prostate Imaging—Reporting and Data System (PI-RADS) version 2.1 in detecting clinically...

Breast Cancer
Genomics/Genetics

Outcomes for BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Therapy

In a single-center study reported in JAMA Network Open, Kerollos Nashat Wanis, MD, PhD, and colleagues found that women with breast cancer and a pathogenic BRCA1/2 variant who underwent breast-conserving therapy had a 71% rate of 10-year bilateral mastectomy–free survival.

Study Details

The study...

Hepatobiliary Cancer

Adjuvant Therapeutic Regimens for Gallbladder Cancer

In an Indian phase II trial (GECCOR-GB) reported in JAMA Oncology, Ostwal et al found that both adjuvant gemcitabine/cisplatin (GC) and capecitabine and capecitabine given concurrently with chemoradiation therapy (CCRT) showed activity in patients with resected gallbladder cancer.

Study Details

In...

Breast Cancer

Stage I HER2-Positive Breast Cancer: Long-Term Follow-up of Adjuvant T-DM1

In a 5-year update of the phase II ATEMPT trial reported in the Journal of Clinical Oncology, Tarantino et al found that 1 year of adjuvant ado-trastuzumab emtansine (T-DM1) was associated with “outstanding” long-term outcomes in patients with stage I HER2-positive breast cancer.

Study Details

In...

Pancreatic Cancer

Surveillance for Pancreatic Cancer in High-Risk Individuals

In a study reported in JAMA Oncology, Blackford et al found that surveillance of individuals at high risk for pancreatic ductal adenocarcinoma allowed for detection of earlier-stage pancreatic ductal adenocarcinoma—with improved survival—compared with matched pancreatic ductal adenocarcinoma...

Issues in Oncology

40% of Cancer Cases and Almost Half of All Cancer Deaths in the United States Linked to Modifiable Risk Factors

A recent study led by researchers at the American Cancer Society has found that 4 in 10 cancer cases and about half of all cancer deaths in adults aged 30 and older in the United States (or 713,340 cancer cases and 262,120 cancer deaths in 2019) may be attributed to modifiable risk factors,...

Breast Cancer
Issues in Oncology

Predicting Taxane-Induced Peripheral Neuropathy After Breast Cancer Therapy

Researchers have developed a novel tool that may help to predict the risk of experiencing peripheral neuropathy following treatment with taxanes in patients with breast cancer, according to a recent study published by Engvall et al in npj Precision Oncology. The findings may aid physicians in...

Colorectal Cancer
Issues in Oncology

RNAs May Help to Identify Patients With Stage II Colorectal Cancer Who May Benefit From Adjuvant Chemotherapy

Investigators have assessed whether RNAs can be used as a biomarker to predict which patients with stage II colorectal cancer may benefit from postsurgical chemotherapy, according to a recent study published by Korsgaard et al in The American Journal of Pathology.

Background

Colorectal cancer is...

Solid Tumors
Issues in Oncology

New Study May Provide Insights Into Immune System Mechanism Shared by Pregnancy and Cancer

By examining the immune system during pregnancy, researchers have uncovered the mechanism that may contribute to oncofetal immune tolerance, according to a recent study published by Yu et al in Cell.

Background

“In pregnancy, the immune system does not reject the growing fetus, so we know there...

Leukemia
Lymphoma
Issues in Oncology

Immunoglobulin G Testing May Reduce Infections, Increase Receipt of Immunoglobulin Replacement Therapy in Patients With CLL and NHL

Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) who undergo frequent immunoglobulin G testing may be less likely to experience severe infections than those who don’t undergo frequent testing, according to a recent study published by Soumerai et al in Blood Advances.

...

Issues in Oncology

Can GLP-1 Receptor Agonists Prevent Obesity-Associated Cancers in Patients With Type 2 Diabetes?

Based on the results of a retrospective U.S. population–based cohort study, which were reported in JAMA Network Open by Wang et al, treatment with glucagon-like peptide 1 (GLP-1) receptor agonists vs insulins seemed to be associated with a decreased risk of developing specific obesity-associated...

Pancreatic Cancer
Immunotherapy

Resected Pancreatic Cancer: Autologous Dendritic Cell Vaccination

In a Dutch single-center phase I/II study reported in the Journal of Clinical Oncology, van ‘t Land et al found that adjuvant autologous dendritic cell vaccination was associated with promising recurrence-free survival in patients who had undergone resection and standard-of-care treatments for...

Prostate Cancer
Genomics/Genetics

Association of Genetic Risk for Prostate Cancer With Early Prostate Cancer Death

In a study reported in JAMA Network Open, Plym et al found that men at a higher genetic risk for prostate cancer were more likely to experience early death from prostate cancer compared to men with a lower genetic risk for the disease.

Study Details

The cohort study used a combined analysis of...

Breast Cancer

Predictive Models for Disease Recurrence After Breast-Conserving Surgery for DCIS

In a Canadian study reported in the Journal of Clinical Oncology, Hahn et al evaluated the impact of certain predictive models for local and invasive local recurrence in patients undergoing breast-conserving surgery with or without adjuvant radiotherapy for pure ductal carcinoma in situ (DCIS).

...

Prostate Cancer
Issues in Oncology

Certain Patients Diagnosed With 'Benign' Classification of Prostate Cancer May Actually Have High-Risk Disease

Recently, some experts have called for Gleason Grade Group 1 prostate cancer to be reclassified as benign. However, many patients diagnosed with this lowest grade of prostate cancer may have more aggressive disease than their biopsy alone suggests, according to a recent study published by Tilki et...

Pancreatic Cancer
Issues in Oncology

Modified Perioperative Chemotherapy Regimen May Benefit Patients With Pancreatic Ductal Adenocarcinoma

Administering chemotherapy prior to and following surgery may extend survival in patients with pancreatic ductal adenocarcinoma compared with postoperative administration alone, according to a recent study published by Cecchini et al in JAMA Oncology. The findings may be encouraging for the 15% to...

Breast Cancer

Factors Impacting Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Breast Cancer

In a Danish study reported in the Journal of Clinical Oncology by Schmidt et al, it was found that living alone and being unemployed were associated with reduced adherence to adjuvant endocrine therapy among premenopausal women with breast cancer.

Study Details

The study involved data from a...

Solid Tumors

Relapsed or Refractory Neuroblastoma: Addition of Dasatinib/Rapamycin to Irinotecan/Temozolomide

In a German-Austrian phase II trial (RIST-rNB-2011) reported in The Lancet Oncology, Corbacioglu et al found that the combination of dasatinib plus rapamycin and irinotecan plus temozolomide (RIST) improved progression-free survival vs irinotecan/temozolomide alone in patients with high-risk...

Gastrointestinal Cancer
Issues in Oncology
Supportive Care

Stiripentol Could Prolong Efficacy of Chemotherapy in Patients With Gastric Cancer

Targeting lactate with the epilepsy drug stiripentol may reverse chemotherapy resistance in patients with gastric cancer, according to a recent study published by Chen et al in Nature.

Background

Chemotherapy attacks cancer cells by damaging their DNA. The cancer cells then try to rapidly repair...

Lymphoma
Issues in Oncology

Infection Risk in Patients With Mantle Cell Lymphoma

Patients with mantle cell lymphoma may be susceptible to certain diseases and may benefit from evaluation for the risk of infection, according to a recent study published by Abalo in HemaSphere.   

Background

“Patients [with mantle cell lymphoma] live with an increased risk of infections for many ...

Skin Cancer

Advanced Melanoma: Efficacy of Monoclonal Antibody Doublet

In a phase I trial reported in the Journal of Clinical Oncology, Omid Hamid, MD, and colleagues found that the combination of the human lymphocyte activation gene-3 (LAG-3)-targeting monoclonal antibody fianlimab plus the PD-1–targeting monoclonal antibody cemiplimab-rwlc was active in patients...

Survivorship
Issues in Oncology

Survivorship Standards at Commission on Cancer–Accredited Cancer Care Facilities

Only a minority of adult cancer survivors may have access to specialized survivorship services such as those addressing fertility and sexual health issues, and having survivorship standards in place may help cancer centers better provide services that meet the distinct needs of these patients,

Survivorship
Supportive Care
Cardio-oncology

Can Adhering to a Mediterranean Diet Reduce Mortality in Cancer Survivors?

Cancer survivors who adhere to a Mediterranean diet may survive longer and have a reduced risk of cardiovascular-related mortality compared with those who had lower adherence to the diet, according to a recent study published by Bonaccio et al in JACC: CardioOncology.

Background

The Mediterranean ...

Head and Neck Cancer

Nasopharyngeal Carcinoma: Adding Sintilimab to Standard Chemoradiotherapy for Locoregionally Advanced Disease

Based on the results of the Chinese multicenter phase III CONTINUUM trial, which were reported in The Lancet by Liu et al, the addition of the PD-1 inhibitor sintilimab to standard chemoradiotherapy seemed to improve event-free survival—albeit with more frequent but manageable adverse events—in...

Bladder Cancer
Kidney Cancer

Advanced/Metastatic Genitourinary Tumors: Cabozantinib/Nivolumab With or Without Ipilimumab

As reported in the Journal of Clinical Oncology by Andrea B. Apolo, MD, and colleagues, findings in expansion cohorts of a phase I study showed the activity of cabozantinib/nivolumab alone or with the addition of ipilimumab in patients with advanced/metastatic genitourinary (GU) tumors.

Study...

Breast Cancer
Supportive Care
Symptom Management
Genomics/Genetics

Germline Risk of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer

Results from the ECOG-ACRIN EAZ171 trial—reported in the Journal of Clinical Oncology by Schneider et al—showed that germline predictors of taxane-induced peripheral neuropathy were not associated with an increased risk of taxane-induced peripheral neuropathy in Black women with early-stage breast...

Issues in Oncology

Tumor Surveillance in Pediatric Patients With Cancer Predisposition Syndromes

In a single-center study reported in JAMA Oncology, Blake et al found that surveillance among pediatric patients with cancer predisposition syndromes can result in the early detection of new tumors. 

As stated by the investigators, “Pediatric oncology patients are increasingly recognized as having ...

Gynecologic Cancers

Endometrial Thickness in Triage for Endometrial Cancer Among Black Women

In a study reported in JAMA Oncology, Kemi Doll, MD, MSCR, and colleagues found that ultrasonography-measured endometrial thickness was not reliable in triage for diagnosing endometrial cancer among Black women.

Study Details

The retrospective U.S. multicenter study focused on data from 1,494...

Skin Cancer
Issues in Oncology

Novel Algorithm May Help to Identify Aggressive Basal Cell Carcinoma

A novel algorithm may help physicians to identify which patients have a highly aggressive subtype of facial basal cell carcinoma, according to a recent study published by Ceder et al in Dermatology Practical & Conceptual.  

Background

Basal cell carcinoma—the most common type of skin...

Gynecologic Cancers
Issues in Oncology

Exploring Health-Care Provider Attitudes Toward HPV Self-Collection Testing

Investigators found that more than 50% of health-care providers surveyed might offer human papillomavirus (HPV) self-collection testing to their patients if the U.S. Food and Drug Administration (FDA) approved the procedure, according to a recent study published by Fontenot et al in Women’s Health...

Solid Tumors
Issues in Oncology

Exercise May Prevent Nerve Damage During Chemotherapy

Physical exercise may help prevent nerve damage in patients receiving chemotherapy, according to a recent study published by Streckmann et al in JAMA Internal Medicine.

Background

Cancer therapies have improved in recent years. Physicians are no longer concerned just about survival; patients’...

Breast Cancer
Issues in Oncology

American Indian and Alaskan Native Women May Be Less Likely to Undergo Breast Reconstruction

Investigators have identified disparities in the rates of breast reconstruction following mastectomy among American Indian and Alaskan Native women compared with non-Hispanic White women, according to a recent study published by White et al in Plastic and Reconstructive Surgery.

Background

Breast ...

Sarcoma

Previously Untreated Intermediate-Risk Rhabdomyosarcoma: Addition of Temsirolimus to Chemotherapy in Young Patients

As reported in The Lancet Oncology by Gupta et al, the phase III Children’s Oncology Group ARST1431 trial showed no event-free survival benefit with the addition of temsirolimus to chemotherapy in previously untreated children, adolescents, or young adults with intermediate-risk rhabdomyosarcoma.

...

Gynecologic Cancers
Leukemia
Survivorship

Risk of Adverse Obstetric Outcomes in Adolescent and Young Adult Cancer Survivors

In an English and Welsh study (The Teenage and Young Adult Cancer Survivor Study) reported in The Lancet Oncology, Sunguc et al found that cervical cancer and leukemia survivors have a heightened risk of experiencing several serious obstetric complications.

“Therefore, any pregnancy [in these...

Prostate Cancer
Issues in Oncology

Radioligand Therapy May Improve Radiographic Progression–Free Survival in Taxane-Naive Patients With Advanced Prostate Cancer

Lutetium (Lu)-177–PSMA-617 radioligand therapy may offer a statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with taxane-naive metastatic castration-resistant prostate cancer, according to findings presented by Herrmann et al at the 2024...

Bladder Cancer

Pembrolizumab in High-Risk Non–Muscle-Invasive Bladder Cancer

As reported in The Lancet Oncology by Andrea Necchi, MD, and colleagues, findings in cohort B of the phase II KEYNOTE-057 study indicated that pembrolizumab was active in patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle invasive bladder cancer. 

As noted by the...

Lung Cancer

Previously Untreated EGFR-Mutated Advanced NSCLC: Amivantamab/Lazertinib vs Osimertinib

As reported in The New England Journal of Medicine by Byoung Chul Cho, MD, PhD, and colleagues, the phase III MARIPOSA trial has shown improved progression-free survival with amivantamab-vmjw plus lazertinib vs osimertinib in previously untreated patients with EGFR-mutated advanced non–small cell...

Hepatobiliary Cancer

Nonplatinum Chemotherapy Regimen for Advanced Cholangiocarcinoma

Based on the results of the multicenter phase II NIFE-AIO-YMO HEP-0315 trial, which were reported in the Journal of Clinical Oncology by Ettrich et al, first-line palliative treatment with nanoliposomal irinotecan plus fluorouracil and leucovorin appears to be safe and active in patients with...

Prostate Cancer
Issues in Oncology

PSA May Be Insufficient to Detect Early Prostate Cancer in Transgender Women

Transgender women receiving hormone therapy may skew artificially low on prostate cancer screening tests, thereby providing false reassurance and potentially delaying diagnosis and treatment, according to a recent study published by Nik-Ahd et al in JAMA. The findings indicated that transgender...

Survivorship
Issues in Oncology

Impact of Cisplatin-Based Chemotherapy on Hearing in Cancer Survivors

Researchers have uncovered the long-term effects of cisplatin-based chemotherapy on the hearing of cancer survivors, according to a recent study published by Sanchez et al in JAMA Oncology.

Background

Cisplatin is commonly used in chemotherapy to treat a variety of cancer types, including...

Multiple Myeloma

Relapsed or Refractory Multiple Myeloma: Activity of BCMA x CD3 Bispecific Antibody

As reported in the Journal of Clinical Oncology by Bumma et al, the phase II portion of a first-in-human phase I/II trial (LINKER-MM1) showed strong activity with the B-cell maturation antigen (BCMA) x CD3 bispecific antibody linvoseltamab in patients with relapsed or refractory multiple myeloma.

...

Kidney Cancer

Perioperative Nivolumab in Renal Cell Carcinoma

As reported in The Lancet Oncology by Allaf et al, a planned interim analysis of the phase III PROSPER ECOG-ACRIN EA8143 trial showed no recurrence-free survival benefit with perioperative nivolumab vs observation in patients undergoing nephrectomy for high-risk renal cell carcinoma. 

Study...

ASCO, Friends of Cancer Research Applaud FDA Draft Guidance

The Association for Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) are applauding efforts by the U.S. Food and Drug Administration (FDA) to broaden eligibility criteria for cancer clinical trials in order to include more diverse patient populations.

In joint comments submitted...

Health-Care Policy

ASCO: SCOTUS Ruling Upends Country’s Regulatory Framework, Threatens to Complicate and Delay Health-Care Delivery

The Association for Clinical Oncology (ASCO) has serious concerns about the impact of the Supreme Court’s rulings in Loper Bright Enterprises v Raimondo and Relentless, Inc. v Department of Commerce on cancer care. These decisions overturned the “Chevron deference” or “Chevron doctrine,” a legal...

Breast Cancer
Supportive Care
Symptom Management
Integrative Oncology

Tai Chi vs Cognitive Behavioral Therapy: Measuring Inflammatory Biomarkers in Breast Cancer Survivors With Insomnia

Both tai chi and cognitive behavioral therapy may reduce insomnia and inflammation and bolster antiviral defenses in breast cancer survivors, according to a recent study published by Irwin et al in Brain, Behavior, and Immunity.  

Background

Chronic insomnia—one of the most prominent symptoms...

Solid Tumors
Issues in Oncology

New Study Demonstrates Similar Outcomes Between Patients With Protocol Exceptions to Participate in Targeted Therapy Trial and Eligible Participants

Patients with treatment-refractory tumors who received eligibility and testing waivers to participate in a large basket/umbrella oncology trial demonstrated similar rates of clinical benefit and adverse events compared with patients who participated in the trial without waivers, according to recent ...

ASCO to Present Ethan Basch, MD, MSc, FASCO, With the Joseph Simone Quality Care Award

ASCO will recognize Ethan Basch, MD, MSc, FASCO, a medical oncologist and Distinguished Professor at the University of North Carolina, with the Joseph Simone Quality Care Award and Lecture at the 2024 ASCO Quality Care Symposium. 

This year’s meeting will be held in San Francisco and online on...

Breast Cancer

Primary Breast Cancer: Pretreatment Exercise Level and Distant Recurrence–Free Interval

In a French study (CANTO) reported in the Journal of Clinical Oncology, Soldato et al found that increasing pretreatment exercise levels was associated with a longer distant recurrence–free interval up to a threshold exercise level in patients with primary breast cancer. The benefit of exercise...

Multiple Myeloma

Transplant-Eligible Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the CASSIOPEIA Trial

As reported in The Lancet Oncology by Philippe Moreau, MD, and colleagues, long-term follow-up of the phase III CASSIOPEIA trial has shown improved progression-free survival with daratumumab maintenance vs observation both among newly diagnosed patients with transplant-eligible multiple myeloma who ...

Hepatobiliary Cancer
Gastroesophageal Cancer
Colorectal Cancer
Issues in Oncology
Supportive Care

Strategies for Reducing the Risk of Cancers in Patients With Alcohol Dependence

Investigators have uncovered the potential benefit of undergoing alcohol rehabilitation and maintaining abstinence in patients with alcohol dependence at risk of developing alcohol-associated cancers, according to a recent study published by Schwarzinger et al in The Lancet Public Health. The...

Skin Cancer
Issues in Oncology

Novel Spatial Gene-Signature Approach May Help to Predict Immunotherapy Outcomes in Patients With Melanoma

Researchers have demonstrated that spatial gene signatures may enhance the prediction of immunotherapy outcomes in patients with melanoma, according to a recent study published by Aung et al in Clinical Cancer Research. The current gene signatures used to predict immunotherapy outcomes may lack...

Colorectal Cancer

Neoadjuvant Combination of PD-1 and Angiogenesis Inhibitors in Genomically Unstable Colorectal Cancer: NEOCAP

As reported in The Lancet Oncology by Yu et al, based on results from the ongoing phase II NEOCAP trial, neoadjuvant therapy with the PD-1 inhibitor camrelizumab plus the angiogenesis inhibitor apatinib appears to demonstrate “promising” antitumor activity and a manageable toxicity profile in...

Breast Cancer
Issues in Oncology

Can Chemotherapy Impact the Gut Microbiome in Patients With Breast Cancer?

Researchers have uncovered the impact of chemotherapy on the gut microbiome in patients with breast cancer, according to a recent study published by Otto-Dobos et al in Brain, Behavior, and Immunity.

Background

Chemotherapy is known to cause behavioral side effects, including cognitive decline....

Kidney Cancer
Issues in Oncology

Novel Biomarker May Be Predictive of Clear Cell Renal Cell Carcinoma Recurrence

Researchers have discovered a biomarker that could help identify which patients with clear cell renal cell carcinoma may be at greater risk of cancer recurrence, according to a recent study published by Mehra et al in JCO Precision Oncology.

Background

Approximately 3% to 5% of all cancer...

Colorectal Cancer

Adding COX-2 Inhibition to Chemotherapy in PIK3CA-Activated Stage III Colon Cancer

In an analysis from the CALGB/SWOG 80702 (Alliance) trial published by Nowak et al in the Journal of Clinical Oncology, researchers found that the addition of the cyclooxygenase 2 (COX-2) inhibitor celecoxib to standard adjuvant chemotherapy was associated with improved disease-free survival and...

Lymphoma

FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma

On June 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to epcoritamab-bysp (Epkinly), a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of systemic therapy.

EPCORE...

Lymphoma

Combination BrECADD Is Significantly More Effective Than BEACOPP for Classical Hodgkin Lymphoma, Study Finds

Although advancements in the treatment of classical Hodgkin lymphoma have increased the 5-year relative survival rate of patients with the disease to nearly 90%, dose-intensified treatment strategies may increase the risk for acute and long-term toxicities.

The German Hodgkin Study Group (GHSG)...

Breast Cancer

ER-Positive Advanced Breast Cancer: Oral SERD Plus Palbociclib in First-Line Setting

As reported in the Journal of Clinical Oncology by Javier Cortés, MD, PhD, and colleagues, the phase III AMEERA-5 trial of first-line treatment with the selective estrogen receptor degrader (SERD) amcenestrant plus palbociclib vs letrozole plus palbociclib in estrogen receptor (ER)-positive,...

Head and Neck Cancer

Recurrent or Metastatic HNSCC: First-Line VEGFR2 Plus PD-1 Inhibition

In a single-center phase I/II trial reported in The Lancet Oncology, Douglas Adkins, MD, and colleagues found that the recommended phase II dose of ramucirumab combined with pembrolizumab was active in the first-line treatment of patients with recurrent or metastatic head and neck squamous cell...

Issues in Oncology

New Survey Finds Cancer Drug Shortage Management Remains a Moving Target

The National Comprehensive Cancer Network® (NCCN®) published new results from its latest survey on cancer drug shortages in the United States. This follows data published 1 year ago and 6 months ago illustrating how up to 93% of centers surveyed were experiencing shortages of the crucial...

Breast Cancer
Supportive Care
Symptom Management

Can Acupuncture Improve Hormonal Side Effects in Women Undergoing Breast Cancer Therapy?

Acupuncture may be effective at reducing the hormonal side effects of endocrine therapy in women with breast cancer, according to a recent study published by Lu et al in Cancer.  

Background

Although endocrine therapy—which is capable of blocking the hormone signaling that drive some types of...

Solid Tumors
Issues in Oncology
Genomics/Genetics

Early Surveillance in Pediatric Patients Genetically Predisposed to Cancer

Initiating surveillance soon after recognizing a pediatric patient has a genetic predisposition for cancer may improve the identification of early-stage asymptomatic tumors, according to a recent study published by Blake et al in JAMA Oncology. The findings may inform clinical practice following...

Lymphoma

Combination Targeted Therapy Produces Durable Responses in Patients With Relapsed DLBCL

The results from a phase Ib/II study of a five-drug regimen of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) show the treatment produced durable remissions in patients with specific molecular...

Skin Cancer

Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma

As reported at the 2024 ASCO Annual Meeting (Abstract 9500) and in The New England Journal of Medicine by Georgina V. Long, MD, PhD, and colleagues, the final, 8-year follow-up analysis of the phase III COMBI-AD trial has shown continued improvements in relapse-free and distant metastasis–free...

Colorectal Cancer

FDA Grants Accelerated Approval to Adagrasib With Cetuximab for KRAS G12C–Mutated Colorectal Cancer

On June 21, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the KRAS G12C inhibitor adagrasib (Krazati) plus cetuximab for adults with KRAS G12C–mutated locally advanced or metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior...

Issues in Oncology
Survivorship

LGBTQ+ Cancer Survivors Have a Higher Burden of Chronic Health Conditions, Disabilities Than Non-LGBTQ+ Cancer Survivors

Although improvements in the early detection and treatment of cancer have reduced cancer-related mortality rates and increased the number of cancer survivors in the United States to over 18 million, not all patients with the disease are benefiting from these advances.

A recent study investigated...

CNS Cancers
Issues in Oncology

Repurposing Brigatinib to Treat NF2-Related Schwannomatosis

Researchers have found that brigatinib may be effective in treating patients with NF2-related schwannomatosis, according to a recent study published by Plotkin et al in The New England Journal of Medicine. The findings revealed a potential new treatment option for the genetic syndrome.

Background

...

Breast Cancer

Socioeconomic Disparities in Quality of Life After Early-Stage Breast Cancer Diagnosis

As reported in the Journal of Clinical Oncology by Sandoval et al, after a diagnosis of early-stage breast cancer, the magnitude of preexisting socioeconomic status–related inequalities in quality of life increased over time for patients in the multicentric French CANTO cohort. 

“When we talk...

Solid Tumors
Cardio-oncology
Issues in Oncology

Air Pollution May Increase Cardiovascular Risk in Patients With Cancer

Air pollution may increase the risk of cardiovascular disease, mortality, and health disparities in patients with cancer, according to a recent study published by Zhu et al in JACC: CardioOncology.

Background

Although modern therapies may help extend the lives of patients with cancer, cancer...

Skin Cancer

Clinical Trial Testing Brenetafusp Plus Nivolumab in Advanced or Metastatic Cutaneous Melanoma Kicks Off

On June 18, the first patient was randomized into the PRISM-MEL-301 trial (ClinicalTrials.gov identifier NCT06112314), which is assessing the efficacy and safety of brenetafusp (also known as IMC-F106C; PRAME-A02) in combination with nivolumab in the first-line setting of advanced or metastatic...

Head and Neck Cancer
Issues in Oncology

Updated ASTRO Clinical Guidelines on Radiation Therapy for HPV-Positive Oropharyngeal Cancer

The American Society for Radiation Oncology (ASTRO) detailed best practices for using radiation therapy as a stand-alone curative treatment or in combination with surgery and/or chemotherapy to treat patients with human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma,

Colorectal Cancer

Metastatic Colorectal Cancer: Addition of Atezolizumab to First-Line FOLFOXIRI/Bevacizumab

As reported in the Journal of Clinical Oncology by Antoniotti et al, 4-year follow-up of the Italian phase II ATEZOTRIBE trial showed a numeric benefit in overall survival with the addition of atezolizumab to first-line FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) and...

Colorectal Cancer
Immunotherapy

Can a Novel Combination Therapy Improve Metastatic Colorectal Cancer Outcomes?

A novel combination comprising experimental immunotherapy drugs plus chemotherapy may improve survival outcomes in previously treated patients with metastatic colorectal cancer compared to the targeted therapy regorafenib alone. These findings will be presented by Wainberg et al at the 2024 ASCO...

Kidney Cancer

Previously Untreated Advanced Clear Cell RCC: Bempegaldesleukin/Nivolumab vs TKI Therapy

As reported in the Journal of Clinical Oncology by Nizar M. Tannir, MD, FACP, and colleagues, the phase III PIVOT-09 trial has shown no objective response or overall survival benefit with bempegaldesleukin plus nivolumab vs tyrosine kinase inhibitor (TKI) treatment with sunitinib or cabozantinib in ...

Colorectal Cancer

Celecoxib May Benefit a Subset of Patients With PIK3CA Mutations

Researchers have found that administering the anti-inflammatory drug celecoxib after surgery may improve disease-free survival in a subset of patients with PIK3CA-mutated stage III colorectal cancer, according to a study published by Nowak et al in the Journal of Clinical Oncology. The findings...

COVID-19

Do Patients With Cancer Require Additional COVID-19 Vaccine Doses?

Findings from a Spanish study on the effectiveness of vaccines against COVID-19 infection among patients with cancer recommend administering additional doses of the vaccine to this at-risk population. These data were published by Neto et al in Nature Communications.

Patients with cancer are at an...

Robert L. Ferris, MD, PhD, Appointed Executive Director of UNC Lineberger Comprehensive Cancer Center

Robert L. Ferris, MD, PhD, a head and neck surgical oncologist, has been named the Executive Director of the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center and UNC System Chief of Oncology Services, effective October 1, announced the Dean of the UNC School of Medicine...

Colorectal Cancer
Breast Cancer
Gynecologic Cancers
Prostate Cancer
Issues in Oncology

Study Evaluates Cancer Screening Behaviors Among a Population of Muslim Individuals

Investigators uncovered crucial insights into the cancer screening behaviors of a population of Muslim individuals residing in the Washington, DC, metropolitan area that could help illuminate the influence of cultural and religious beliefs on health practices, according to a recent study published...

Bladder Cancer

High-Risk Non–Muscle-Invasive Bladder Cancer: Reduced Induction Courses of BCG

As reported by Katims et al in JAMA Oncology, long-term follow-up of a single-center phase II study showed benefit with two induction courses of bacillus Calmette-Guérin (BCG) without maintenance in patients with high-risk non–muscle-invasive bladder cancer. The strategy markedly reduced the number ...

Bladder Cancer

FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer

On April 22, the U.S. Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva) with bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

QUILT-3.032 Trial

Efficacy ...

Hepatobiliary Cancer
Genomics/Genetics

Machine-Learning Model May Aid in Early Diagnosis of Hepatocellular Carcinoma

A serum fusion-gene machine-learning model may offer early diagnostic accuracy and could help improve the 5-year survival rate in patients with hepatocellular carcinoma, according to a recent study published by Yu et al in The American Journal of Pathology.

Background

Hepatocellular carcinoma is...

Solid Tumors
Hematologic Malignancies
Immunotherapy

Risk of Secondary Cancer After CAR T-Cell Therapy

In a single-center study reported in The New England Journal of Medicine, Hamilton et al found that second tumors had occurred in 25 of 724 patients during 15 months of follow-up after receipt of chimeric antigen receptor (CAR) T-cell therapy, including one fatal case of T-cell lymphoma.

The study ...

Gastroesophageal Cancer

Esophageal Cancer: Neoadjuvant Triplet or Doublet Chemotherapy, With or Without Radiotherapy

As reported in The Lancet by Ken Kato, MD, and colleagues, the Japanese phase III JCOG1109 NExT trial showed that neoadjuvant triplet chemotherapy was associated with superior overall survival vs doublet chemotherapy among previously untreated patients with locally advanced esophageal squamous cell ...

Breast Cancer
Issues in Oncology
Supportive Care

FAPI PET/CT May Improve Staging in Newly Diagnosed Breast Cancer

Researchers have found that fibroblast activation protein inhibitor (FAPI) positron-emission tomography/computed tomography (PET/CT) may offer more accurate staging in patients with newly diagnosed breast cancer than fluorine (F)-18–labeled fluorodeoxyglucose (FDG) PET/CT, according to new findings ...

Lung Cancer

Lorlatinib vs Crizotinib in Previously Untreated Advanced ALK-Positive NSCLC

As reported in the Journal of Clinical Oncology by Benjamin J. Solomon, MBBS, PhD, and colleagues, analysis of 5-year outcomes in the phase III CROWN trial showed that median progression-free survival had not been reached in previously untreated patients receiving lorlatinib vs a median of 9.1...

Pancreatic Cancer

Previously Untreated Metastatic Pancreatic Cancer: CD40 Agonist Plus mFOLFIRINOX

In a European phase Ib/II study (OPTIMIZE-1) reported in The Lancet Oncology, Jean-Luc Van Laethem, MD, and colleagues found that the combination of the CD40 agonist antibody mitazalimab with mFOLFIRINOX (modified fluorouracil, leucovorin, oxaliplatin, and irinotecan) showed activity in previously...

Supportive Care

Carboplatin-Induced Nausea and Vomiting: Addition of Olanzapine to Triple Antiemetic Therapy

In a Japanese phase III trial reported in the Journal of Clinical Oncology, Inui et al found that the addition of olanzapine to triple antiemetic therapy did not improve the prevention of carboplatin-induced vomiting in patients with thoracic cancers who had received no prior chemotherapy; however, ...

Sarcoma
Solid Tumors
Issues in Oncology

Can FAP-Targeted Radioligand Therapy Benefit Patients With Advanced Sarcomas?

Fibroblast activation protein (FAP)-targeted radioligand therapy may be safe and effective in patients with progressive metastatic tumors, particularly advanced sarcomas, according to new findings presented by Lanzafame et al at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI)...

Breast Cancer

Efficacy of Adjuvant Everolimus Plus Endocrine Therapy in High-Risk, Hormone Receptor–Positive, HER2-Negative Breast Cancer

As reported in the Journal of Clinical Oncology by Mariana Chavez-MacGregor, MD, MSc, FASCO, and colleagues, the phase III SWOG S1207 trial showed no significant benefit in invasive disease–free survival with adjuvant endocrine therapy plus 1 year of everolimus vs 1 year of placebo in patients with ...

Gynecologic Cancers

FDA Approves Two Immunochemotherapy Combinations for Endometrial Cancer

On June 17, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with carboplatin and paclitaxel followed by single-agent pembrolizumab for adult patients with primary advanced or recurrent endometrial carcinoma; on June 14, the agency approved durvalumab...

Solid Tumors
Issues in Oncology

Using a Novel AI Tool for Cancer Detection on Whole-Body PET/CT Scans

A novel artificial intelligence (AI) tool may accurately detect six different types of cancers on whole-body positron-emission tomography/computed tomography (PET/CT) scans and automatically quantify tumor burden to assess patient risk, treatment response, and survival, according to new findings...

Leukemia

FDA Approves Blinatumomab as Consolidation for CD19-Positive, Ph-Negative B-Cell Precursor ALL

On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved blinatumomab (Blincyto) for adult and pediatric patients aged 1 month and older with CD19-positive, Philadelphia chromosome (Ph)-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of...

Prostate Cancer
Issues in Oncology
Supportive Care

Chelating Agent May Reduce Toxicity Associated With PSMA Radiopharmaceutical Therapy

A novel chelator may significantly reduce off-target toxicity in prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy, according to new findings presented by Ho et al at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting (Abstract 242340).

Background

...

Colorectal Cancer
Issues in Oncology

Pretargeted Dual-Isotope Radionuclide Therapy in Colorectal Cancer

A combination of alpha- and beta-radionuclide therapy may be feasible, tolerable, and effective in colorectal cancer, according to preclinical findings presented by Rinne et al at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting (Abstract 241498). The new approach...

Breast Cancer
Issues in Oncology

Novel ctDNA Liquid Biopsy May Help Predict Breast Cancer Recurrence Years Before Relapse

A novel ultrasensitive liquid biopsy may be predictive of breast cancer recurrence up to years prior to relapse in high-risk patients with early breast cancer, according to recent findings presented by Garcia-Murillas et al at the 2024 ASCO Annual Meeting (Abstract 1010).

Background

Circulating...

Breast Cancer

T-DXd Improves Progression-Free Survival in Patients With Breast Cancer Previously Treated With Endocrine Therapy

Fam-trastuzumab deruxtecan-nxki (T-DXd) delayed cancer growth in patients with hormone receptor (HR)-positive, HER2-low or -ultralow metastatic breast cancer that progressed following endocrine therapy, according to findings from the phase III DESTINY-Breast06 trial. The research was presented by...

Advertisement

Advertisement




Advertisement